Related Experiment Video
Updated: Aug 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
HIV and hepatitis C co-infection
1Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, London, UK.
Insights
HIV/HCV co-infection significantly impacts patient health. Recent trials offer hope for improved treatment outcomes in individuals with both HIV and Hepatitis C virus infections.
Area of Science:
- Infectious Diseases
- Hepatology
- Virology
Background:
- HIV/HCV co-infection is a growing global health concern.
- Understanding co-infection dynamics is crucial for patient management.
- Hepatitis C virus (HCV) acquisition factors and disease progression in HIV patients require thorough examination.
Purpose of the Study:
- To review the prevalence of HIV/HCV co-infection.
- To analyze factors contributing to HCV acquisition in co-infected individuals.
- To assess the impact of co-infection on disease progression and treatment efficacy.
Main Methods:
- Review of major co-infection clinical trials (APRICOT, ACTG 5071, RIBAVIC).
- Analysis of existing evidence on HCV acquisition and disease progression in HIV patients.
- Examination of emerging therapeutic strategies for co-infected individuals.
Main Results:
- Co-infection significantly increases morbidity and mortality.
- Key trials provide insights into treatment responses.
- Emerging therapies show promise for improved outcomes.
Conclusions:
- HIV/HCV co-infection presents a substantial clinical challenge.
- Clinical trials and ongoing research offer optimism for effective management.
- Future therapies may enhance treatment success rates in co-infected populations.
Abstract:
HIV/HCV co-infection is emerging as a major cause of morbidity and mortality in the 21st century. This editorial reviews the prevalence of co-infection, the factors involved in acquisition of HCV, and the influence of co-infection on disease progression. We examine the results of the major co-infection trials including APRICOT, ACTG 5071 and RIBAVIC. These trials, in association with emerging evidence for future therapies currently undergoing investigation, have led to increased hope of treatment success in co-infected individuals.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Sexually Transmitted Infections
Cytomegalovirus Disease
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
